Showing 1 - 6 results of 6 for search 'Valeria Rachela Villella', query time: 0.03s Refine Results
  1. 1
    Immuno-Sensing at Ultra-Low Concentration of TG2 Protein by Organic Electrochemical Transistors

    Immuno-Sensing at Ultra-Low Concentration of TG2 Protein by Organic Electrochemical Transistors by Valentina Preziosi, Mario Barra, Valeria Rachela Villella, Speranza Esposito, Pasquale D’Angelo, Simone Luigi Marasso, Matteo Cocuzza, Antonio Cassinese, Stefano Guido

    Published 2023-03-01
    Get full text
    Article
  2. 2
    Organic Electrochemical Transistor Immuno-Sensors for Spike Protein Early Detection

    Organic Electrochemical Transistor Immuno-Sensors for Spike Protein Early Detection by Mario Barra, Giovanna Tomaiuolo, Valeria Rachela Villella, Speranza Esposito, Aris Liboà, Pasquale D’Angelo, Simone Luigi Marasso, Matteo Cocuzza, Valentina Bertana, Elena Camilli, Valentina Preziosi

    Published 2023-07-01
    Get full text
    Article
  3. 3
    L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients

    L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro gu... by Stefania Lo Cicero, Germana Castelli, Giovanna Blaconà, Sabina Maria Bruno, Giovanni Sette, Riccardo Pigliucci, Valeria Rachela Villella, Speranza Esposito, Immacolata Zollo, Francesca Spadaro, Ruggero De Maria, Mauro Biffoni, Giuseppe Cimino, Felice Amato, Marco Lucarelli, Adriana Eramo

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients

    Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoid... by Stefania Lo Cicero, Germana Castelli, Giovanna Blaconà, Sabina Maria Bruno, Giovanni Sette, Riccardo Pigliucci, Valeria Rachela Villella, Speranza Esposito, Immacolata Zollo, Francesca Spadaro, Ruggero De Maria, Mauro Biffoni, Giuseppe Cimino, Felice Amato, Marco Lucarelli, Adriana Eramo

    Published 2023-09-01
    Get full text
    Article
  5. 5
    The STING/TBK1/IRF3/IFN type I pathway is defective in cystic fibrosis

    The STING/TBK1/IRF3/IFN type I pathway is defective in cystic fibrosis by Luca Occhigrossi, Federica Rossin, Valeria Rachela Villella, Speranza Esposito, Speranza Esposito, Carlo Abbate, Manuela D’Eletto, Maria Grazia Farrace, Antonella Tosco, Roberta Nardacci, Roberta Nardacci, Gian Maria Fimia, Gian Maria Fimia, Valeria Raia, Valeria Raia, Mauro Piacentini, Mauro Piacentini

    Published 2023-02-01
    Get full text
    Article
  6. 6
    IL-9 and Mast Cells Are Key Players of Candida albicans Commensalism and Pathogenesis in the Gut

    IL-9 and Mast Cells Are Key Players of Candida albicans Commensalism and Pathogenesis in the Gut by Giorgia Renga, Silvia Moretti, Vasilis Oikonomou, Monica Borghi, Teresa Zelante, Giuseppe Paolicelli, Claudio Costantini, Marco De Zuani, Valeria Rachela Villella, Valeria Raia, Rachele Del Sordo, Andrea Bartoli, Monia Baldoni, Jean-Christophe Renauld, Angelo Sidoni, Enrico Garaci, Luigi Maiuri, Carlo Pucillo, Luigina Romani

    Published 2018-05-01
    Get full text
    Article

Search Tools: